Company intelligence / Profile preview

Teal Omics

Cambridge, Massachusetts, United Statestealomics.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Teal Omics is developing a proprietary AI-driven proteomics platform to identify organ-specific aging signatures. Their research has been published in Nature, demonstrating the ability to track health and disease through plasma proteome analysis. The company is focused on enabling precision medicine approaches for chronic age-related diseases by uncovering previously undetectable biological triggers of degeneration.[1]

Therapeutic areas: Neurology
Modalities: BiomarkersProteomics-based therapeuticsArtificial intelligence/machine learning-driven drug discovery[1][4]
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Teal Omics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teal Omics.

Explore the full profile